KB-707 Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving KB-707 Growth

1. Novel localized cytokine delivery platform (core scientific advantage)

KB-707 uses a genetically engineered HSV-1 vector to express IL-12 and IL-2 directly within tumors, enabling:

• High local immune activation
• Reduced systemic cytokine toxicity compared with IV IL-2/IL-12

This approach is designed to overcome long-standing limitations of cytokine therapy (toxicity + short half-life), a key bottleneck highlighted across cytokine immunotherapy literature (Journal of Clinical Oncology, cytokine delivery studies).

• Driver: differentiated tumor-localized immune activation platform

2. Early clinical efficacy signals in heavily pretreated patients

In early Phase I/II NSCLC data presented at ASCO 2026:

• KB-707 + pembrolizumab showed ~31.3% objective response rate (ORR) in evaluable patients
• Disease control rate ~75%
• Some patients achieved durable partial responses

These results are notable given:

• Median patient age ~72
• Heavily pretreated population (median 3 prior lines)
• Driver: early proof-of-concept activity in checkpoint-refractory tumors

3. Strong synergy potential with checkpoint inhibitors (PD-1/LAG-3 axis)

KB-707 is actively being tested with:

• Pembrolizumab (Keytruda)
• Nivolumab + relatlimab (Opdualag)

Clinical trial design explicitly evaluates combination cohorts in melanoma and NSCLC.

Mechanistic rationale:

• IL-12 enhances Th1-driven cytotoxic immunity
• IL-2 expands activated T-cell populations
• Checkpoint inhibitors remove T-cell exhaustion brakes
• Driver: combination immunotherapy amplification strategy

4. Intratumoral + inhaled delivery enabling tissue-specific targeting

KB-707 is delivered via:

• Intratumoral injection (melanoma/solid tumors)
• Nebulized inhalation (lung cancers/NSCLC)

This dual-route strategy:

• Concentrates therapy in tumor sites
• Reduces systemic exposure
• Enables access to lung-resident tumors that are hard to inject directly
• Driver: physically targeted gene delivery improving safety and feasibility

5. Expansion into multiple solid tumor indications (platform scalability)

Current clinical programs include:

• Advanced melanoma (dose expansion cohorts)
• NSCLC (lung-directed inhaled program)
• Other metastatic solid tumors

Trial design explicitly includes multiple tumor types and combination arms, suggesting a platform rather than single-indication drug strategy.

• Driver: multi-tumor expansion potential beyond lead indications

KB-707 Recent Developments

In February 2026, Krystal Biotech announced that the United States Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, the Company's redosable immunotherapy designed to drive sustained, localized expression of interleukin-2 and interleukin-12 in the tumor microenvironment, for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC).

"KB-707 Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of KB-707 for potential indication like Lung cancer, Non-small cell lung cancer, and Solid tumours in the 7MM. A detailed picture of KB-707's existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the KB-707 for potential indications. The KB-707 market report provides insights about KB-707's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current KB-707 performance, future market assessments inclusive of the KB-707 market forecast analysis for potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of KB-707 sales forecasts, along with factors driving its market.

KB-707 Drug Summary

KB-707 is an investigational immune-modulating therapy designed to regulate and enhance anti-tumor immune responses through engineered cytokine signaling, with a particular focus on the interleukin-2 (IL-2) pathway. It is being developed to selectively influence immune cell activation-aiming to expand and activate cytotoxic T cells and natural killer (NK) cells while improving the pharmacologic limitations of native cytokines such as short half-life and dose-limiting toxicity. By leveraging protein engineering approaches, KB-707 is intended to achieve a more controlled and sustained immune stimulation within the tumor microenvironment, potentially improving tumor recognition and immune-mediated clearance in oncology settings. It is administered in clinical research settings via parenteral routes and remains in early-stage development, with ongoing evaluation of its safety, pharmacokinetics, and preliminary anti-tumor activity. The report provides KB-707's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the KB-707 Market Report

The report provides insights into:

• A comprehensive product overview including the KB-707 MoA, description, dosage and administration, research and development activities in potential indication like Lung cancer, Non-small cell lung cancer, and Solid tumours.
• Elaborated details on KB-707 regulatory milestones and other development activities have been provided in KB-707 market report.
• The report also highlights KB-707's cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The KB-707 market report also covers the patents information, generic entry and impact on cost cut.
• The KB-707 market report contains current and forecasted KB-707 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The KB-707 market report also features the SWOT analysis with analyst views for KB-707 in potential indications.

Methodology:

The KB-707 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

KB-707 Analytical Perspective by DelveInsight

• In-depth KB-707 Market Assessment

This KB-707 sales market forecast report provides a detailed market assessment of KB-707 for potential indication like Lung cancer, Non-small cell lung cancer, and Solid tumours in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted KB-707 sales data uptil 2034.

• KB-707 Clinical Assessment

The KB-707 market report provides the clinical trials information of KB-707 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

KB-707 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

KB-707 Market Potential & Revenue Forecast

• Projected market size for the KB-707 and its key indications
• Estimated KB-707 sales potential (KB-707 peak sales forecasts)
• KB-707 Pricing strategies and reimbursement landscape

KB-707 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• KB-707 Market positioning compared to existing treatments
• KB-707 Strengths & weaknesses relative to competitors

KB-707 Regulatory & Commercial Milestones

• KB-707 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

KB-707 Clinical Differentiation

• KB-707 Efficacy & safety advantages over existing drugs
• KB-707 Unique selling points

KB-707 Market Report Highlights

• In the coming years, the KB-707 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The KB-707 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence KB-707's dominance.
• Other emerging products for Lung cancer, Non-small cell lung cancer, and Solid tumours are expected to give tough market competition to KB-707 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of KB-707 in potential indications.
• Analyse KB-707 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted KB-707 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of KB-707 in potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of KB-707? How strong is KB-707's clinical and commercial performance?
• What is KB-707's clinical trial status in each individual indications such as Lung cancer, Non-small cell lung cancer, and Solid tumours and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the KB-707 Manufacturers?
• What are the key designations that have been granted to KB-707 for potential indications? How are they going to impact KB-707's penetration in various geographies?
• What is the current and forecasted KB-707 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of KB-707 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to KB-707 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is KB-707? What is the duration of therapy and what are the geographical variations in cost per patient?